Bilgen: Small R&D teams own products and report directly to co-founders
Ozan Bilgen · BillionToOne Is Solving One of Biotech’s Hardest Problems · Y Combinator · Apr 6, 2026 · at 15:51
Oguzhan Atay, co-founder and CEO of BillionToOne, details the company's internal organizational structure for research and development.
0:00 / 0:22exact quote · 22.3s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“We actually have very small you know, research teams. It is essentially principal investigators, like a scientist who is interdisciplinary, who has a small team of, you know, two or three research associates, and they all directly report to David and me, and they own end-to-end development of an entire product.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Ozan Bilgen
Bilgen: MRD cancer detection shares same technical challenge as population screening
“If you can detect a microscopic level of DNA and be able to say that that is actually cancer, that is the same really technical problem as being able to detect those in healthy patients or, you know, general population.”
Bilgen: Interdisciplinary scientists accelerate R&D by an order of magnitude
“We have found that having that iterative cycle within one scientist actually accelerates the work that they do by an order of magnitude.”
Bilgen: Direct early cancer detection requires raising over $1B pre-revenue
“If you wanted to solve early detection from the very beginning without having this step-by-step approach, you would have to raise more than a billion dollars, you know, without generating a single dollar of revenue.”
Bilgen: BillionToOne Processes Over 600,000 Tests Annually With ~20% Market Share
“We are processing more than 600,000 tests a year, and in terms of the overall market share, We are close to 20% market share there.”
Bilgen: Synthetic DNA removes PCR amplification noise from sequencing data
“So what we have done is to add a synthetic DNA into the patient sample that we get before any amplification happens. These synthetic DNA Allow us to know how much amplification happened at different genomic locations. You know, what are the errors that are bei…”